Chemistry:MT-1207

From HandWiki

MT-1207 is a combined serotonin 5-HT2A receptor antagonist, α1-adrenergic receptor antagonist, and calcium channel blocker which is under development for the treatment of hypertension (high blood pressure).[1][2][3][4][5] It is taken orally.[2] The drug's time to peak levels is 0.5 to 1.25 hours and its elimination half-life is 4 to 7 hours.[5] MT-1207 is under development in China.[2] As of 2025, MT-1207 has reached phase 2 clinical trials.[1][2]

References

  1. ↑ 1.0 1.1 "Delving into the Latest Updates on MT-1207 with Synapse". 12 January 2026. https://synapse.patsnap.com/drug/7b66f49260da4d7d80263aff36e7d60e. 
  2. ↑ 2.0 2.1 2.2 2.3 "MT-1207 Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/23715. 
  3. ↑ "Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension". Journal of Medicinal Chemistry 67 (18): 16128–16144. September 2024. doi:10.1021/acs.jmedchem.4c00626. PMID 38968440. https://nottingham-repository.worktribe.com/output/37283463. 
  4. ↑ "Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent". Acta Pharmacologica Sinica 42 (6): 885–897. June 2021. doi:10.1038/s41401-021-00636-1. PMID 33782540. 
  5. ↑ 5.0 5.1 "Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects". Expert Opinion on Investigational Drugs 30 (3): 271–278. March 2021. doi:10.1080/13543784.2021.1887137. PMID 33560891. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MT-1207&oldid=4244420"